NASDAQ:IVVD

Invivyd (IVVD) Stock Forecast, Price & News

$1.64

-0.02 (-1.20%)

(As of 10:21 AM ET)

Compare

Today's Range: $1.60
▼
$1.66
50-Day Range: $1.35
▼
$1.89
52-Week Range: $0.98
▼
$4.09

Volume: 7,684 shs
Average Volume: 280,566 shs
Market Capitalization: $180.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Invivyd MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 82.9% Upside
$3.00 Price Target
Short Interest: Healthy
4.88% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.87) to ($0.72) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

619th out of 964 stocks

Biological Products, Except Diagnostic Industry

95th out of 160 stocks

3.0

Analyst's Opinion

Consensus Rating
Invivyd has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Invivyd has a forecasted upside of 82.9% from its current price of $1.64.
Amount of Analyst Coverage
Invivyd has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
4.88% of the float of Invivyd has been sold short.
Short Interest Ratio / Days to Cover
Invivyd has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Invivyd has recently decreased by 18.14%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Invivyd does not currently pay a dividend.
Dividend Growth
Invivyd does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IVVD.

0.6

News and Social Media Coverage

Search Interest
Only 1 people have searched for IVVD on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
1 people have added Invivyd to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Invivyd insiders have not sold or bought any company stock.
Percentage Held by Insiders
19.10% of the stock of Invivyd is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
50.94% of the stock of Invivyd is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Invivyd are expected to grow in the coming year, from ($1.87) to ($0.72) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Invivyd is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Invivyd is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Invivyd has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

IVVD Price History

30 days | 90 days | 365 days | Advanced Chart

IVVD Stock News Headlines

September 11, 2023 | benzinga.com

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

September 6, 2023 | finance.yahoo.com

Invivyd to Participate in Upcoming Investor Conferences

September 22, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"

The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>

September 5, 2023 | seekingalpha.com

Invivyd gets new finance chief

September 5, 2023 | markets.businessinsider.com

Invivyd Appoints William Duke As New CFO

September 5, 2023 | finance.yahoo.com

Invivyd Appoints William Duke as Chief Financial Officer

August 29, 2023 | finance.yahoo.com

Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why

August 15, 2023 | finance.yahoo.com

Invivyd, Inc. (NASDAQ:IVVD) Q2 2023 Earnings Call Transcript

September 22, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"

August 14, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Invivyd (IVVD)

August 10, 2023 | finance.yahoo.com

Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

August 3, 2023 | finance.yahoo.com

Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights

July 28, 2023 | finance.yahoo.com

Invivyd Announces Appointment of Sara Cotter to Board Of Directors

July 22, 2023 | businesswire.com

INVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI

July 17, 2023 | finance.yahoo.com

Invivyd's COVID-19 Antibody Shows Favorable Safety, Tolerability Profile For Immunocompromised People

July 17, 2023 | finance.yahoo.com

Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

June 26, 2023 | tmcnet.com

Invivyd Announces General Alignment with FDA on Pathway

June 23, 2023 | markets.businessinsider.com

What 4 Analyst Ratings Have To Say About Invivyd

June 22, 2023 | finance.yahoo.com

Invivyd Says Investigational Antibody Shows Potential To Prevent Symptomatic COVID-19

May 23, 2023 | finance.yahoo.com

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

May 12, 2023 | marketwatch.com

Invivyd Reports First Quarter 2023 Financial Results and Business Highlights

May 11, 2023 | msn.com

Invivyd: Q1 Earnings Insights

May 11, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Esperion (ESPR), Invivyd (IVVD)

May 10, 2023 | msn.com

4IVVD : Earnings Preview: Invivyd

May 4, 2023 | finance.yahoo.com

Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights

April 25, 2023 | benzinga.com

Invivyd to Participate at H.C. Wainwright's BioConnect Investor Conference

April 25, 2023 | finance.yahoo.com

Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference

See More Headlines

Receive IVVD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter.

IVVD Company Calendar

Last Earnings: 8/10/2023
Today: 9/21/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:IVVD
CUSIP: N/A
CIK: 1832038
Web: adagiotx.com
Phone: 781-819-0080
Fax: N/A
Employees: 84
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: +80.7%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-241,320,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -52.25%
Return on Assets: -47.56%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.54
Quick Ratio: 9.54

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.27 per share
Price / Book: 0.51

Miscellaneous

Outstanding Shares: 109,756,000
Free Float: 88,793,000
Market Cap: $182.19 million
Optionable: Optionable
Beta: -0.12

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. David Hering M.B.A. (Age 47)
CEO & Director
Comp: $932.5k

Ms. Jill Andersen J.D. (Age 50)
Chief Legal Officer & Corp. Sec.
Comp: $619.33k

Mr. William E. Duke Jr. (Age 51)
M.B.A., Chief Financial Officer

Mr. Jeremy Gowler (Age 46)
Chief Operating Officer & Chief Commercial Officer

Ms. Stacy Price M.S. (Age 54)
Chief Technology & Manufacturing Officer

Dr. Robert D. Allen Ph.D.
Chief Scientific Officer

Ms. Julie Green M.B.A.
Sr. VP of HR

Dr. Peter C. Schmidt M.D. (Age 42)
M.S., M.Sc., Chief Medical Officer

Ms. Heidi Spurling M.S.
VP of Strategy & Operations and Chief of Staff to the CEO

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

IVVD Stock - Frequently Asked Questions

Should I buy or sell Invivyd stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invivyd in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" IVVD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IVVD, but not buy additional shares or sell existing shares.
View IVVD analyst ratings or view top-rated stocks.
What is Invivyd's stock price forecast for 2023?: 2 Wall Street analysts have issued twelve-month target prices for Invivyd's stock. Their IVVD share price forecasts range from $1.00 to $5.00. On average, they predict the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 80.7% from the stock's current price.
View analysts price targets for IVVD or view top-rated stocks among Wall Street analysts.
How have IVVD shares performed in 2023?: Invivyd's stock was trading at $1.50 at the start of the year. Since then, IVVD shares have increased by 10.7% and is now trading at $1.66.
View the best growth stocks for 2023 here.
Are investors shorting Invivyd?: Invivyd saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 1,940,000 shares, a drop of 18.1% from the August 15th total of 2,370,000 shares. Based on an average daily volume of 387,900 shares, the short-interest ratio is presently 5.0 days. Currently, 4.9% of the shares of the stock are short sold.
View Invivyd's Short Interest.
When is Invivyd's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our IVVD earnings forecast.
How were Invivyd's earnings last quarter?: Invivyd, Inc. (NASDAQ:IVVD) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.06.

What ETF holds Invivyd's stock ?: ETFMG Treatments Testing and Advancements ETF holds 30,909 shares of IVVD stock, representing 0.32% of its portfolio.
What is Invivyd's stock symbol?: Invivyd trades on the NASDAQ under the ticker symbol "IVVD."
Who are Invivyd's major shareholders?: Invivyd's stock is owned by a variety of institutional and retail investors. Top institutional investors include 683 Capital Management LLC (3.64%), Citigroup Inc. (2.13%), BlackRock Inc. (1.20%), Geode Capital Management LLC (0.47%), Charles Schwab Investment Management Inc. (0.26%) and RBF Capital LLC (0.19%).
How do I buy shares of Invivyd?: Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Invivyd's stock price today?: One share of IVVD stock can currently be purchased for approximately $1.66.
How much money does Invivyd make?: Invivyd (NASDAQ:IVVD) has a market capitalization of $182.19 million. The company earns $-241,320,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis.
How can I contact Invivyd?: Invivyd's mailing address is 1601 TRAPELO ROAD SUITE 178, WALTHAM MA, 02451. The official website for the company is adagiotx.com. The company can be reached via phone at 781-819-0080 or via email at investors@adagiotx.com.

This page (NASDAQ:IVVD) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial